Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Hot Flashes 2

Interventions

Docetaxel 69pembrolizumab 48Prednisone 43Nivolumab 40enzalutamide 38Gemcitabine 37Sunitinib 36Cyclophosphamide 29Radiotherapy 26Magnetic Resonance Spectroscopy 26Leuprolide 25Abiraterone Acetate 25Sorafenib 23Everolimus 23Cisplatin 23bicalutamide 19atezolizumab 18Carboplatin 18Bevacizumab 18avelumab 17Radiosurgery 17Goserelin 17Interleukin-2 16abiraterone 15fludarabine 14Doxorubicin 14olaparib 13durvalumab 13cabozantinib 13acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Venlafaxine Hydrochloride × Genitourinary × Clear all
NCT00354432 2021-09-28

Soy Protein/Effexor Hormone Therapy for Prostate Cancer

Wake Forest University Health Sciences

Phase 3 Terminated
120 enrolled 11 charts
Genitourinary

Prostatic Neoplasms, Hot Flashes

NCT01533753 2019-11-21

Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer

University of Wisconsin, Madison

Phase 2 Terminated
5 enrolled 5 charts
Genitourinary

Prostatic Neoplasms, Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡